Rob ten Hoedt joins Supervisory Board

https://nlc-health.webflow.io/news/rob-ten-hoedt-joins-supervisory-board

Anne Reijns

Dec 2020

•

5 min read

Anne Reijns

Dec 2020

•

5 min read

Read article on external website

We are pleased to announce that Rob ten Hoedt has agreed to join NLC’s Supervisory Board per December 1st 2020. Rob is Executive Vice President and President EMEA at Medtronic, and Chair and Member of the Operations Management Committee of the board of MedTech Europe.His extensive knowledge of the Health Tech field and his substantial network will enable us to make even more impact in our mission to advance health, accessible for everyone. We feel privileged to be able to welcome Rob on our team!

Share this post

News

Insights

Jul 2024

Insights

Nina Rijnders: Impact investing for philanthropic fund (In Dutch)

Insights

Nina Rijnders: Impact investing for philanthropic fund (In Dutch)

Nina Rijnders: Impact investing for philanthropic fund (In Dutch)

SERDA Therapeutics Announces Completion of First Phase 1 Clinical Study of SN514

SERDA Therapeutics Announces Completion of First Phase 1 Clinical Study of SN514

Introducing Exolvo: NLC Health Ventures launches new early-stage drug delivery company

Introducing Exolvo: NLC Health Ventures launches new early-stage drug delivery company

Dutch health insurer VGZ invests in NLC Health Ventures

Dutch health insurer VGZ invests in NLC Health Ventures

NLC was named the Number 1 Most Active Early Stage Investor in Healthcare in Europe by Financial Times’ Sifted

NLC was named the Number 1 Most Active Early Stage Investor in Healthcare in Europe by Financial Times’ Sifted

NLC venture Altach secures €1.2 million investment to transform treatments for cartilage injuries

NLC venture Altach secures €1.2 million investment to transform treatments for cartilage injuries

NLC completes first close of €100 million health impact fund

NLC completes first close of €100 million health impact fund

AI Healthtech start-up MindAffect raises €1.1 million to transform hearing diagnostics

AI Healthtech start-up MindAffect raises €1.1 million to transform hearing diagnostics

IPD secures funding of €2.1 million to initiate its first-in-human trials for prosthetic joint infections

IPD secures funding of €2.1 million to initiate its first-in-human trials for prosthetic joint infections

Introducing Aerion Bioscience: A new era of cancer screening

Introducing Aerion Bioscience: A new era of cancer screening

CUIP and NLC Health Ventures signed a MoU to bring cutting-edge innovations to life

CUIP and NLC Health Ventures signed a MoU to bring cutting-edge innovations to life

POROUS wins innovation award

POROUS wins innovation award

Ansana secures a €850,000 investment

Ansana secures a €850,000 investment

Introducing LiftYa: Stability with motion

Introducing LiftYa: Stability with motion

Introducing StarTric: Transcatheter tricuspid heart valve repair

Introducing StarTric: Transcatheter tricuspid heart valve repair

Introducing Amotio: Revolutionising orthopaedic revision surgery: An innovative approach to major joint implant revisions

Introducing Amotio: Revolutionising orthopaedic revision surgery: An innovative approach to major joint implant revisions

NLC was named the Number 1 Most Active Early Stage Investor in Healthcare in Europe by Financial Times’ Sifted.

NLC was named the Number 1 Most Active Early Stage Investor in Healthcare in Europe by Financial Times’ Sifted.

Introducing our newest venture ChARM: Empowering low-resource healthcare professionals around the world

Introducing our newest venture ChARM: Empowering low-resource healthcare professionals around the world

Introducing our newest venture: Asclepius

Introducing our newest venture: Asclepius

Introducing our venture Nilocas: A cardiac device for the detection of coronary artery disease

Introducing our venture Nilocas: A cardiac device for the detection of coronary artery disease